These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 14983624)

  • 61. Medicare program: Medicare Advantage and Prescription Drug Benefit programs: final marketing provisions. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2008 Sep; 73(182):54207-23. PubMed ID: 18985950
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Health and Wellness Trust Fund Commission funds prescription drug programs in North Carolina.
    Perdue BE
    N C Med J; 2003; 64(6):283-4. PubMed ID: 14983618
    [No Abstract]   [Full Text] [Related]  

  • 63. Unraveling the effects of tier-copayment drug benefit designs.
    Curtiss FR
    J Manag Care Pharm; 2003; 9(2):177-8. PubMed ID: 14613348
    [No Abstract]   [Full Text] [Related]  

  • 64. 2007 costs and coverage of antiretrovirals under Medicare Part D for people with HIV/AIDS living in North Carolina.
    Sengupta S
    N C Med J; 2008; 69(1):6-13. PubMed ID: 18429558
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Can e-prescribing reduce drug costs under capitation?
    Capitation Manag Rep; 2002 Apr; 9(4):58-62, 49. PubMed ID: 12004737
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Holding down prescription drug costs.
    FDA Consum; 1975 Dec-1976 Jan; 9(10):9-10. PubMed ID: 10305011
    [No Abstract]   [Full Text] [Related]  

  • 67. Border crossing.
    Fuller C
    Revolution (Oakl); 2003; 4(5):24-9. PubMed ID: 14631721
    [No Abstract]   [Full Text] [Related]  

  • 68. Should drug prices be negotiated under part D of Medicare? And if so, how?
    Frank RG; Newhouse JP
    Health Aff (Millwood); 2008; 27(1):33-43. PubMed ID: 18180478
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Medicare Part D: primer.
    Coakley C
    Adv Nurse Pract; 2006 Sep; 14(9):24. PubMed ID: 16972439
    [No Abstract]   [Full Text] [Related]  

  • 70. Six questions to ask when eyeing Medicare pharmacy risk.
    Public Sect Contract Rep; 1998 Aug; 4(8):117-20. PubMed ID: 10182906
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Congress shapes a prescription drug benefit.
    Baxter MD
    Oncologist; 2003; 8(4):392-4. PubMed ID: 12897337
    [No Abstract]   [Full Text] [Related]  

  • 72. Prescription drugs and medical costs: four opportunities for health plans and physicians to make a difference.
    Greczyn RJ
    N C Med J; 2003; 64(6):285-6. PubMed ID: 14983619
    [No Abstract]   [Full Text] [Related]  

  • 73. Medicare agreement: premium support demo ... maybe.
    Med Health; 2003 Nov; 57(43):1-2. PubMed ID: 14723114
    [No Abstract]   [Full Text] [Related]  

  • 74. Pharmaceutical insurance and the demand for prescription pharmaceuticals in Västerbotten, Sweden.
    Rudholm N
    Scand J Public Health; 2005; 33(1):50-6. PubMed ID: 15764241
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmaceuticals: Medicare Modernization Act--2005. End of Year Issue Brief.
    Seay M
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-21. PubMed ID: 16710928
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmaceutical price controls at the state level.
    Kozma CM
    Manag Care Interface; 2001 Jul; 14(7):59-60. PubMed ID: 11481818
    [No Abstract]   [Full Text] [Related]  

  • 77. [Family physicians resist high prescription risk].
    Schmidt K
    MMW Fortschr Med; 2003 May; 145(20):58. PubMed ID: 12822233
    [No Abstract]   [Full Text] [Related]  

  • 78. Perspective. Easy fix for high drug costs? Guess again, America.
    Med Health; 2004 Apr; 58(17):1, 7-8. PubMed ID: 15148716
    [No Abstract]   [Full Text] [Related]  

  • 79. DAKOTACARE update: What are we doing about prescription costs?
    Krafka TL
    S D Med; 2007 Jun; 60(6):243-4. PubMed ID: 17649865
    [No Abstract]   [Full Text] [Related]  

  • 80. Medicare coverage of prescription drugs.
    Division of Advocacy and Health Policy
    Bull Am Coll Surg; 2005 Sep; 90(9):29-30, 62. PubMed ID: 18435099
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.